<DOC>
	<DOCNO>NCT02435108</DOCNO>
	<brief_summary>This pilot study crizotinib patient c-MET positive gastric adenocarcinoma .</brief_summary>
	<brief_title>A Pilot Study Crizotinib Patients With c-MET Positive Gastric Adenocarcinoma Third-line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Patients must â‰¥20 year age . 3 . Advanced gastric adenocarcinoma ( include GEJ ) progress second line therapy . 4. cMET positive gastric cancer 5 . ECOG PS 02 6 . At least one measurable disease 7 . Proper organ function 1. severe comorbid illness and/or active infection 2. pregnant lactate woman 3 . History document congestive heart failure ; angina pectoris require medication ; evidence tranasmural myocardial infarction ECG ; poorly control hypertension ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia 4. active CNS metastasis controllable radiotherapy corticosteroid ( however , CNS metastases ( except leptomeningeal seed ) allow control gamma knife surgery surgery radiotherapy steroid ) 5. know history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MET poisitivity define least half tumor cell show weak , moderate high staining</keyword>
</DOC>